Leukemia is classified into types based on two factors: how fast it grows (acute or chronic) and which white blood cell lineage it affects (lymphoid or myeloid). This produces four main types, with hairy cell leukemia commonly recognized as a fifth. The overall five-year survival rate for leukemia is 68.6%, though outcomes vary dramatically depending on the specific type, the patient’s age, and how early it’s caught.
How Leukemia Types Are Classified
Your bone marrow produces two broad families of white blood cells: lymphocytes, which target viruses and coordinate immune responses, and myeloid cells, which fight bacteria and help with wound healing. Leukemia starts when one of these cell lines begins growing out of control.
Acute leukemias develop rapidly. The cancerous cells are immature and can’t perform normal immune functions. Chronic leukemias grow more slowly in cells that are further along in their development. These cells can still do some of their job, just not well. Combining these two speed categories with the two cell lineages gives you the four primary types, and the fifth, hairy cell leukemia, is a rare chronic form that doesn’t fit neatly into the other categories.
Acute Lymphoblastic Leukemia (ALL)
ALL is the most common cancer in children, originating in immature lymphocytes in the bone marrow and thymus. It progresses quickly and requires prompt treatment. The good news is that survival rates for childhood ALL have improved dramatically over the past several decades. For children under 15, the five-year survival rate is now approximately 90%. For adolescents aged 15 to 19, it has climbed from 36% in the 1975-1984 period to 78% in recent years.
Adults can develop ALL too, though it’s less common and generally harder to treat than the childhood form. ALL affects the B cells or T cells of the immune system, and knowing which subtype a patient has helps doctors choose the most effective treatment approach.
Acute Myeloid Leukemia (AML)
AML is the most common acute leukemia in adults, and its risk increases with age. It starts in the myeloid cell line, the cells that would normally become bacteria-fighting white blood cells. The cancer tends to involve genetic changes in the leukemia cells, including mutations in genes that control cell growth and survival. These mutations accumulate more frequently as people age, which helps explain why AML is primarily a disease of older adults.
Because AML is acute, it develops fast and can cause symptoms within weeks. Immature, nonfunctional cells flood the bone marrow and crowd out healthy blood cells, leading to infections, anemia, and bleeding problems. Treatment typically involves intensive chemotherapy, and in some cases, a stem cell transplant.
Acute Promyelocytic Leukemia (APL)
APL is a specific subtype of AML that’s worth knowing about because it behaves differently and has its own targeted treatment. It involves a very particular genetic change and, when caught early, has one of the highest cure rates of any adult leukemia. Some classifications list it as a separate type, though it technically falls under the AML umbrella.
Chronic Lymphocytic Leukemia (CLL)
CLL is the most common leukemia in adults in Western countries. It grows slowly in mature lymphocytes and is often discovered by accident during routine blood work, before a person has any symptoms at all. Many people live with CLL for years without needing treatment, a strategy doctors call “watch and wait.”
When CLL does progress, it’s staged using a system that tracks how far the disease has spread through the body. Early stages involve only elevated lymphocyte counts in the blood, with normal red blood cell and platelet levels. As the disease advances, it causes enlarged lymph nodes, then an enlarged spleen or liver, and eventually anemia or low platelet counts. Not everyone progresses through all these stages, and some people remain in early stages for decades.
Chronic Myeloid Leukemia (CML)
CML has one of the most well-understood genetic causes of any cancer. In nearly all cases, it’s driven by an abnormal chromosome called the Philadelphia chromosome, created when pieces of chromosomes 9 and 22 accidentally swap places. This swap creates a fused gene that produces a protein acting like a permanently stuck “on” switch for cell growth. The protein activates multiple signaling pathways that tell myeloid cells to keep dividing and to resist the normal signals that would trigger cell death.
Understanding this mechanism led to the development of targeted drugs that block the faulty protein. Before these drugs existed, CML was often fatal within a few years. Now, most people with CML who respond to treatment have a near-normal life expectancy. CML typically moves through three phases: a slow chronic phase that can last years, an accelerated phase, and a fast-moving blast crisis that resembles acute leukemia.
Hairy Cell Leukemia (HCL)
Hairy cell leukemia gets its name from the fine, hair-like projections visible on the cancer cells under a microscope. It’s a rare, slow-growing leukemia that affects B lymphocytes and accounts for only about 2% of all leukemia cases. The hallmark physical finding is a massively enlarged spleen, present in virtually every patient. More than 80% have significant spleen enlargement, and about one in four experience abdominal discomfort from it.
Despite its rarity, HCL responds very well to treatment. Most patients achieve long-lasting remissions, and many are effectively cured with a single course of therapy.
Symptoms Shared Across All Types
Regardless of the specific type, leukemia disrupts normal blood cell production. This means the warning signs tend to overlap. Common symptoms include persistent fatigue, frequent or severe infections, unexplained weight loss, and fevers or chills. You might notice easy bruising, recurrent nosebleeds, or tiny red spots on the skin called petechiae, all signs that your platelet count is low. Night sweats, bone pain, and swollen lymph nodes or a feeling of fullness below the ribs (from an enlarged spleen or liver) are also common.
Acute leukemias tend to cause symptoms that come on suddenly and worsen over days to weeks. Chronic leukemias may produce mild or no symptoms for months or years before being detected.
How Doctors Determine the Type
Identifying the exact type of leukemia matters because each one has different treatment strategies and prognoses. The process usually starts with a complete blood count that shows abnormal white blood cell numbers. A bone marrow biopsy provides a direct look at the cells being produced. From that sample, a technique called flow cytometry sorts cells by their surface markers, identifying whether the leukemia is T cell, B cell, or myeloid in origin. This helps narrow the diagnosis and guide treatment decisions. Flow cytometry results are always interpreted alongside the cell’s appearance under a microscope and other genetic tests, since no single test gives the full picture on its own.